Scheumann G F, Seeliger H, Musholt T J, Gimm O, Wegener G, Dralle H, Hundeshagen H, Pichlmayr R
Department of Abdominal and Transplantation Surgery, Hannover Medical School, Germany.
Eur J Surg. 1996 Sep;162(9):677-84.
To evaluate the prognostic factors that influence survival and recurrence after "completion" thyroidectomy (removal of the total thyroid remnant after diagnosis of carcinoma has been made in a specimen that was incompletely excised for a benign condition).
Open study.
Teaching hospital, Germany.
131 Patients (65 with papillary and 66 with follicular thyroid cancer) who underwent completion thyroidectomy after primary subtotal resection.
Indications for further operation were: tumour stage worse than pT1 ( n = 116), tumour stage pT1 and the suspicion of persistence of the tumour (n = 13), and incompletely resected tumour (n = 2). Multivariate analysis by Cox's proportional hazards model.
Recurrence, development of metastases, and length of survival.
Patients who underwent their completion thyroidectomies within six months of the primary operation had significantly fewer recurrences, fewer lymph node metastases, fewer haematogenous metastases and survived significantly longer than those in whom the second operation was delayed for longer than six months. The age at the time of diagnosis and the stage of the tumour influenced survival, whereas sex and type of tumour did not.
Completion thyroidectomy as soon as possible after incomplete resection of the tumour may improve prognosis in differentiated thyroid cancers the stage of which is worse than pT1 or in patients whose recurrent tumour is diagnosed at follow-up.
评估影响“根治性”甲状腺切除术(即在因良性疾病而未完全切除的标本中诊断出癌后切除全部甲状腺残余组织)后生存及复发的预后因素。
开放性研究。
德国教学医院。
131例在初次次全切除术后接受根治性甲状腺切除术的患者(65例乳头状甲状腺癌患者和66例滤泡状甲状腺癌患者)。
进一步手术的指征为:肿瘤分期比pT1期差(n = 116)、肿瘤分期为pT1期且怀疑肿瘤持续存在(n = 13)以及肿瘤切除不完全(n = 2)。采用Cox比例风险模型进行多因素分析。
复发、转移发生情况及生存时长。
在初次手术后6个月内接受根治性甲状腺切除术的患者,其复发、淋巴结转移及血行转移均显著少于手术延迟超过6个月的患者,且生存时间显著更长。诊断时的年龄及肿瘤分期影响生存,而性别及肿瘤类型则无此影响。
肿瘤切除不完全后尽早进行根治性甲状腺切除术,可能改善分化型甲状腺癌(分期比pT1期差)或随访时诊断为复发性肿瘤患者的预后。